IMSound is a new audio series developed and produced by the International Myeloma Society. In this series, we invite KOL to give short presentations about hot button issues facing the global myeloma community.
Click on an episode to play, download, or share.
More episodes will be released soon so stay tuned for more!
Series 2
The second series of IMSound is dedicated to the cutting-edge myeloma abstracts that were selected as oral presentations at the 66th ASH Annual Meeting and Exposition that took place in December 2024.
More episodes will be posted soon so visit this page for regular updates.
Preliminary Results from the IMMagine-1 Trial
Ciara Freeman
Final Progression-Free Survival Analysis of Part 1 of an Open-Label, Multicenter, Randomized, Phase 3 Trial (GMMG-HD7)
Hartmut Goldschmidt
A Dexamethasone Sparing-Regimen with Daratumumab and Lenalidomide for Frail Patients with Newly-Diagnosed Multiple Myeloma
Salomon Manier
First Results of a Phase 1, First-in-Human, Dose Escalation Study of ISB 2001, a BCMAxCD38xCD3 Targeting Trispecific Antibody in Patients with Relapsed/Refractory Multiple Myeloma (RRMM)
Hang Quach
Results from the GMMG-HD10/DSMM-XX (MajesTEC-5) Trial
Marc S. Raab
Safety Run-in (SRI) Results from the Majestec-4/EMN30 Trial
Elena Zamagni
Overall Survival Analysis and Updated Efficacy Outcomes of the Phase 3 Dreamm-7 Trial
Vania Hungria
Special Edition Series at the 2024 IMS Annual Meeting
During the 2024 IMS Annual Meeting, we have invited abstract authors to give insights into the research they are presenting. Visit this page each day of the IMS Annual Meeting for updates.
Single cell analyses of bone marrow immune microenvironment in RRMM subjects treated with MEK1/2 inhibitors reveal IRF1-mediated IFN/PDL1 signaling axes
Chaitanya Acharya
Single-cell RNA-sequencing of 6 million tumor and immune cells in patients with plasma cell premalignancy unveils co-regulation of disease progression by tumor biology and immune dysregulation
Romanos Sklavenitis-Pistofidis
Efficacy and safety of Isa-KRd induction before response-adapted consolidation in transplant eligible newly diagnosed multiple myeloma: an interim analysis of the IFM2020-02 MIDAS study.
Aurore Perrot
Safety and Efficacy of Standard of Care Ciltacabtagene Autoleucel (Cilta-cel) for Relapsed/Refractory Multiple Myeloma (RRMM): Real World Experience With Updated Follow-up
Surbhi Sidana
Series 1:
Recorded May-July 2024
Importance of Patient-Reported Symptoms and Health-Related Quality of Life for drug approval in multiple myeloma
Michel Delforge, MD, PhD
Prevention of infections during treatment with bispecific antibodies and CAR T cells in multiple myeloma
Heinz Ludwig, MD
Development of an academic CAR-T in MM : the Spanish experience
Carlos Fernández de Larrea
Drug access in Brazil; equity actions between Public and Private Health Systems
Angelo Maiolino, MD, PhD
Optimal therapy for young patients with high-risk disease: the European point of view
Katja Weisel, MD
Do we need PET-CT to assess response in multiple myeloma?
Elena Zamagni, MD, PhD
Findings from the Australian and New Zealand myeloma and related diseases registry
Andrew Spencer, MD, PhD
Resistance to bispecific antibodies
Paola Neri, MD, PhD
Role of tandem autologous stem cell transplantation for the treatment of multiple myeloma
Mohamad Mohty, MD, PhD
Ongoing clinical trials from the Nordic Group
Fredrik Schjesvold, MD, PhD
Frontline Therapy for transplant ineligible patients: the European perspective
Xavier Leleu, MD, PhD
Why Become a Member
The International Myeloma Society is a professional, scientific, and medical society established to bring together clinical and experimental scientists involved in the study of myeloma. The purpose of this society is to promote research, education, clinical studies (including diagnosis and treatment), workshops, conferences, and symposia on all aspects of multiple myeloma worldwide.
The IMS is a membership organization comprised of basic research scientists, and clinical investigators in the field along with physicians and other healthcare practitioners.
